



Bristol-Myers Squibb Australia Pty Ltd
ABN 33 004 333 322

PO Box 1080, Mt Waverley VIC 3149
Level 2, 4 Nexus Court, Mulgrave
Ph. 03 8523 4200
www.bmsa.com.au

1st December 2016

Dear Health Care Professional

Bristol-Myers Squibb (BMS) will cease supply of Modecate (fluphenazine decanoate) injection and expect supply to be depleted between March and August 2017.

Fluphenazine decanoate is indicated for the long-term management of psychotic disorders including schizophrenia. Prior to making this decision, Bristol-Myers Squibb carefully evaluated the potential impact on patients and concluded that there are comparable therapeutic alternatives available.

Our decision to discontinue the product is consistent with the company's focus on discovering, developing and delivering innovative medicines in its core therapeutic areas, which are immuno-oncology, immunoscience, cardiovascular disease, fibrotic disease and genetically defined disease.

This action is not related to any product safety or efficacy issue.

We recognise that a change of medication for this patient population may be challenging so it is important that treating doctors consider possible alternatives and a transition plan.

Please do not hesitate to contact customer service on 1800 629 273 should you have any queries.

Kind regards

A handwritten signature in black ink, appearing to read 'Jonathan Anderson', with a long horizontal flourish extending to the right.

Dr Jonathan Anderson
Country Medical Director, Australia and New Zealand
MBChB FRACGP MSc MPH PhD